Physician profile
David Kulling
NPI 1528028800
$1,820.39
in general payments reported to CMS, 2019-2025
23 companies · $473 in 2025
The $473 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $385 · 2021: $144 · 2022: $337 · 2023: $38.54 · 2024: $444 · 2025: $473.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $955.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $954.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $400.62 | 2019-2025 | Trelegy Ellipta, Bexsero, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $261.13 | 2019-2025 | Farxiga, Airsupra |
| Lilly USA, LLC | $219.80 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $179.30 | 2022-2025 | |
| Novo Nordisk INC | $116.77 | 2019-2024 | Ozempic |
| Pfizer INC. | $96.37 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $71.60 | 2019 | |
| Viiv Healthcare Company | $67.65 | 2022-2024 | Dovato |
| Gilead Sciences, INC. | $61.09 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $56.47 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Boehringer Ingelheim Pharmaceuticals, INC. | $44.97 | 2021-2022 | |
| Seqirus USA INC | $35.75 | 2025 | Fluad, Flucelvax |
| Exact Sciences Corporation | $32.76 | 2025 | The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $30.01 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $23.48 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $20.05 | 2025 | Zurzuvae |
| Esperion Therapeutics, INC. | $19.02 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $18.29 | 2025 | Austedo Xr |
| Phathom Pharmaceuticals, INC. | $14.53 | 2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $13.72 | 2022 | |
| Novartis Pharmaceuticals Corporation | $13.33 | 2022 | |
| Sanofi-Aventis U.S. LLC | $11.92 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kulling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.